**PRESS RELEASE**
05 November 2025 11:00:00 CET

# ALLIGATOR BIOSCIENCE PRESENTS NEW DATA ON MITAZALIMAB AND ATOR-4066 AT SITC 40TH ANNIVERSARY ANNUAL MEETING

**Lund, Sweden – 5 November 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of two abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held 5–9 November 2025 in National Harbor, MD, USA.**

The mitazalimab abstract presents new data from the OPTIMIZE-1 trial in metastatic pancreatic cancer, further characterizing efficacy, safety, and biomarker responses at two dose levels. These findings strengthen the clinical rationale for selecting the 900 µg/kg dose in the planned Phase 3 study and the exposure-response data further supports mitazalimab contribution to the clinical benefits observed in OPTIMIZE-1. Alligator will also present preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, demonstrating immune activation and remodeling of the tumor microenvironment.

---

**Mitazalimab presentation details**
**Title:** CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 study
**Abstract number:** 530
**Time:** Saturday, 8 November 2025
**Presenter:** Yago Pico de Coaña, Medical Science Director, Alligator Bioscience

*Key findings:*

- **Improved survival outcomes at 6 months**:
  - PFS: 50.8% vs. 38.7%
  - OS: 89.5% vs. 69.4%

- **Manageable safety profile**: Safety was manageable across both dose levels, with the increased rate of adverse events in the 900 µg/kg group attributed to extended treatment exposure
- **Biomarker analyses**: Greater immune activation at 900 µg/kg, including higher levels of Ki67+ T cells, a marker of actively dividing and proliferating immune cells
- **Dose selection for Phase 3**: Data support 900 µg/kg as the recommended dose for the planned Phase 3 study in metastatic pancreatic cancer

**PRESS RELEASE**
05 November 2025 11:00:00 CET

**ATOR-4066 presentation details**
**Title:** ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces potent anti-tumor activity that associates with activated intra-tumoral immune cells and disassembly of extracellular tumor matrix
**Abstract number:** 940
**Time:** Saturday, 8 November 2025
**Presenter:** Hampus Andersson, Industrial PhD student, Alligator Bioscience

*Key findings:*

- **Localized immune activation:** Enhanced dendritic cell and macrophage activation, uptake of tumor antigens, and priming of neoantigen-specific T cells
- **Potent anti-tumor activity:** Superior efficacy compared to CD40 monospecific antibodies in preclinical tumor models
- **Tumor microenvironment remodeling:** Downregulation of extracellular matrix (ECM) organization genes and upregulation of ECM disassembly pathways, correlating with increased immune cell infiltration

"The new OPTIMIZE-1 data provide important validation of mitazalimab's therapeutic potential in metastatic pancreatic cancer and further strengthen the rationale for the planned Phase 3 study using the 900 µg/kg dose level," said **Søren Bregenholt, CEO of Alligator Bioscience**. "This is a significant milestone for Alligator as we prepare mitazalimab for late-stage development. In addition, we are pleased to share encouraging preclinical results for ATOR-4066, underscoring the breadth and innovation of our pipeline."

The abstracts are available at **www.sitcancer.org/2025**.

**For further information, please contact:**

Søren Bregenholt, CEO
E-mail: **soren.bregenholt@alligatorbioscience.com**
Phone: +46 (0) 46 540 82 00

*The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on 5 November 2025.*

**PRESS RELEASE**
05 November 2025 11:00:00 CET

## About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit **alligatorbioscience.com**.

## Attachments

**Alligator Bioscience presents new data on mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting**